Betagenon AB
Umeå
About Betagenon AB
Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. Their lead AMPK activator compound O304 is currently in Phase IIa clinical trial.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Funding stage: M&A
- Last round: Series Unknown (Jun 2021)
- Website: betagenon.se
- Phone: +46 90154822
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/betagenon-ab-122674 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.